Table 3 Antipsychotic treatment, route of distribution and substance by proportion of patients with dispensed prescription in 2012

Antipsychotic medication

(N = 7284)

(N = 11,485)

Per oral^a

55.5

41.9

1.32

Long-term injectables^a

10.3

2.05

5.01

Per oral and long-term injectables^a

12.5

2.9

4.26

No antipsychotic medication^a

21.6

53.1

0.41

Substance

Schizophrenia (%)

NAP (%)

RR

95% CI

 Olanzapine^a

21.4

16.4

1.33

 Zuclopenthixol^a

14.1

3.3

4.24

 Risperidone^a

12.9

9.9

1.30

 Perphenazine^a

12.8

4.7

2.72

 Haloperidol^a

12.6

6.4

1.95

 Clozapine^a

11.6

1.2

9.63

 Aripiprazole^a

9.2

6.0

1.54

 Quetiapine^a

7.1

8.2

0.86

 Flupentixol^a

3.9

2.7

1.42

 Paliperidone^a

3.8

1.3

2.92

 Ziprasidone

1.4

1.0

1.30

 Chlorprothixene

0.8

0.06

1.33

 Fluphenazine^a

0.3

0.05

6.31

 Melperone

0.2

0.1

1.58

 Thioridazine

0.1

0.05

2.36

 Chlorpromazine^a

0.1

0.02

6.31

 Sertindole

0.06

0.02

3.15

 Sulpiride

0.04

0

–

 Cyamemazine

0.01

0

–

 Pimozide

0.01

0

–